Advancing the science in clinical trials for new TB drugs

International Journal of Tuberculosis and Lung Disease

Volumn 12, Issue 2, 2008, Pages 111-112

  Burman, William ^a   McNeeley, David ^b   Moulton, Lawrence H ^c   Spigelman, Melvin ^d   Vernon, Andrew ^e  

^a DENVER PUBLIC HEALTH   (United States)

^b Tibotec   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d TB Alliance   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GATIFLOXACIN; MOXIFLOXACIN;

BACTERIUM CULTURE; CLINICAL TRIAL; EDITORIAL; HEALTH PROGRAM; HUMAN; LUNG TUBERCULOSIS; MEDICAL RESEARCH; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL;

ANIMALS; ANTITUBERCULAR AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; SPUTUM; TUBERCULOSIS, PULMONARY;

EID: 38949159144     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (12)

1. Rustomjee R, Lienhardt C, Kanyok T, et al., and the Gatifloxacin for TB (OFLOTUB) study team. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacins in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008; 12: 128-138.
2. Ginsberg A M, Spigelman M. Challenges in tuberculosis drug research and development. Nat Med 2007; 13: 290-294.
3. Yee D, Valiquetee C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am Rev Respir Crit Care Med 2003; 167: 1472-1477.
4. Teleman M D, Chee C B E, Earnest A, Wang Y T. Hepatotoxity of tuberculosis chemotherapy under general programme conditions in Singapore. Int J Tuberc Lung Dis 2002; 6: 699-705.
5. Burman W J, Goldberg S, Johnson J L, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006; 174: 331-338.
6. Fox W, Ellard G A, Mitchison D A. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3 (Suppl 2): S231-S279.
7. Mitchison D A. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis 1993; 147: 1062-1063.
8. Brindle R, Odhiambo J, Mitchison D A. Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilizing activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis. BMC Pulm Med 2001; 1: 2-9.
9. Davies G R, Brindle R, Khoo S H, Aarons L J. Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment. Antimicrob Agents Chemother 2006; 50: 3154-3156.
10. Joloba M L, Johnson J L, Namale A, et al. Quantitative sputum bacillary load during rifampin-containing short course chemotherapy in human immunodeficiency virus-infected and non-infected adults with pulmonary tuberculosis. Int J Tuberc Lung Dis 2000; 4: 528-536.
11. Dorman S, Johnson J, Padayatchi N, Goldberg S, Bozeman L, Chaisson R. Moxifloxacin vs. isoniazid in the first 2 months of treatment for pulmonary tuberculosis. 47th ICAAC, 2007: Abstr. L-736b.
12. Chaisson R E, Conde M, Efron A, et al. A randomized, placebo-controlled trial of moxifloxacin vs. ethambutol in the initial phase of tuberculosis therapy in Brazil. 47th ICAAC, 2007: Abstr. L-736a.